Jun 22, 2020
Phio Presents Additional Data Supporting Potential of TIGIT Targeting INTASYL Compound in the Tumor Microenvironment at AACR 2020
Jun 22, 2020
Rakuten Medical Presents Data Characterizing how Photoimmunotherapy Induces Cancer Cell Death and Enhances the Immune Response Preclinically
Jun 22, 2020
Dracen announces two DRP-104 presentations at AACR
Jun 11, 2020
Egle Therapeutics Enters Into a Corporate Strategic Research Alliance with Takeda to Uncover Novel Tumor-specific Regulatory T-cell Targets and Develop Unique Anti-Suppressor-Based Immunotherapies
Jun 11, 2020
Kymera Therapeutics to Disclose IRAKIMiD Degrader Program and Present Preclinical Data Demonstrating Potent Immunomodulatory and Antitumor Activity for its Novel STAT3 Degraders in Immuno-oncology
May 29, 2020
PathAI Demonstrates the Potential of AI-based Characterization of the Tumor Microenvironment at ASCO
May 29, 2020
Phio Announces Positive In Vivo Data on the Intratumoral Use of INTASYL Compounds Showing Strong Antitumor Activity
Apr 09, 2020
Vigeo Therapeutics Doses First Patients in Expansion Phase of its 1b/2 Study Investigating VT1021 in Patients with CD36 Expressing Cancers
Mar 31, 2020
Phio Announces Positive New Data Validating the INTASYL(TM) Immunotherapy Platform's Ability to Develop Novel Compounds Capable of Inhibiting Cancer Tumor Growth
Mar 26, 2020
Phio Pharmaceuticals Reports Year End 2019 Financial Results and Provides Business Update
Mar 23, 2020
First-of-its-kind Engineered Macrophage Cell Therapy Platform Shows Ability to Reduce Tumor Burden and Activate Anti-Tumor Immunity, Improving Overall Survival in Pre-Clinical Cancer Models
Mar 16, 2020
EnGeneIC Announces Publication in Cancer Cell of a Scientific Paper Highlighting the Ability of EDV(TM) Nanocells to Mount Dual Assault on Cancer Cells
Mar 12, 2020
IsoPlexis Launches Suite of New Products Enabling Multiple Automated Applications on the IsoLight
Jan 08, 2020
Agenus Commences Phase 1 trial with AGEN1223
Jan 07, 2020
Curis Announces Option and License Agreement with ImmuNext for the Development and Commercialization of Anti-VISTA Antibodies
Dec 12, 2019
CStone completes registration filing for the Phase I trial of its tumor immune microenvironment modulator CS3005 to enable study initiation in Australia
Dec 05, 2019
Screen Therapeutics enters into an immuno-oncology drug development partnership with Immunaccel
Nov 19, 2019
Torque Presents Preclinical Data for Lead Deep-Primed Cellular Immunotherapy Programs at AACR 2019 Special Conference on Tumor Immunology and Immunotherapy
Nov 16, 2019
Carisma Therapeutics Announces Investor Conference Participation
Nov 08, 2019
BERG Presents Data Demonstrating That BPM31510 Promotes Cytotoxic T-cell Function And Influences Checkpoint Receptor Expression Patterns To Potentially Synergize Anti-Cancer Effect In Combination With I/O Therapies